Table 1 Statistical analyses of the prognostic variables for OS in the training cohort

From: The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era

Baseline variable

HR

95% CI

P-value

Univariate Cox regression analyses for OS

 Age >60 years

2.109

1.043–4.265

0.038

 LDH ⩽1 × ULN

1

—

—

 LDH >1 × ULN, ⩽3 × ULN

4.339

2.205–8.539

<0.001

 LDH >3 × ULN

12.257

5.752–26.118

<0.001

 Ann Arbor stage III–IV

3.13

1.779–5.507

<0.001

 ECOG-PS ⩾2

6.498

3.958–10.670

<0.001

 CRP >1.0 mg/dl

4.336

2.605–7.217

<0.001

 ALB <3.5 mg/dl

5.592

3.273–9.554

<0.001

 Extranodal diseasea

3.324

2.048–5.397

<0.001

Multivariate Cox regression analyses of variables for OS selected by backward stepwise regression

 LDH ⩽1 × ULN

1

—

—

 LDH >1 × ULN, ⩽3 × ULN

2.472

1.203–5.078

0.014

 LDH >3 × ULN

3.688

1.571–8.657

0.003

 ECOG-PS ⩾2

2.496

1.401–4.448

0.002

 ALB <3.5 mg/dl

2.523

1.358–4.688

0.003

 Extranodal diseasea

1.713

1.031–2.844

0.038

  1. Abbreviations: ALB, albumin; CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; PS, performance status; ULN, upper limit of normal range.
  2. aLymphoma involvement in the bone marrow, bone, skin or lung/pleura.
Back to article page